Aditxt Signed Definitive Agreement Valuing Ignite Proteomics at Approximately $150 Million
June 9, 2026
Aditxt Announces Proposed Public Offering of Common Stock and Warrants
November 30, 2021
Related Post
-
-
AIM ImmunoTech Announces $2.65 Million Financing Priced At-Market under NYSE American Rules
June 9, 2026
-
Cartesian Therapeutics Announces Strategic Licensing Agreement with WestGene Biopharma to Accelerate the Development of In Vivo CAR-T Platform in Autoimmune Diseases
June 9, 2026
-
Soligenix Applying for Vaccine Development Funding for Bundibugyo Ebola Vaccine
June 8, 2026